GSK Bribery Scandal in China: Case Study Analysis
This case study examines the GlaxoSmithKline (GSK) bribery scandal that surfaced in China in 2013, in which the company was accused of funnelling approximately £323 million through travel agencies to bribe doctors and government officials into prescribing its higher-priced drugs. The paper analyzes the business, cultural, and regulatory conditions that contributed to the scandal, including China's competitive pharmaceutical market, systemic corruption in hospital drug pricing, and weak judicial enforcement of anti-bribery laws. It evaluates GSK's corporate response, considers whether the company was treated fairly by Chinese authorities, and draws lessons for executives planning to expand operations into China while navigating the U.S. Foreign Corrupt Practices Act and the U.K. Bribery Act.
- Introduction and Background: GSK scandal overview and paper scope
- Market Conditions and Causes of the Bribery Scandal: Why systemic corruption enabled GSK's misconduct
- GSK's Corporate Response and Ethical Obligations: Apologies, suspensions, and internal policy changes
- Fairness of Prosecution and Regulatory Accountability: Whether GSK was selectively targeted by authorities
- Compliance Strategies and Anti-Bribery Frameworks: Recommended legal and ethical safeguards for multinationals
- Conclusions and Lessons Learned: Three strategic lessons for entering China
✍️ How to write this paper — guide, tools & examples ▾
What makes this paper effective
- Grounds ethical analysis in specific, verifiable facts — the £323 million bribery figure, the $490 million fine, and China's Transparency International ranking — rather than relying on abstract claims alone.
- Balances competing perspectives by acknowledging systemic factors (hospital pricing culture, low conviction rates, domestic competitor norms) without excusing GSK's conduct, demonstrating nuanced ethical reasoning.
- Connects micro-level corporate behavior to macro-level regulatory frameworks (FCPA and UK Bribery Act), making the analysis practically useful for an executive audience.
Key academic technique demonstrated
The paper applies stakeholder and consequentialist ethical reasoning to a real corporate scandal, evaluating harms to end-users (drug price inflation), autonomy violations (doctor prescription coercion), and reputational damage — then translating those findings into concrete compliance recommendations. This technique shows how ethical theory can drive actionable business strategy.
Structure breakdown
The paper opens with background on GSK and the Chinese pharmaceutical market, moves through five numbered analytical sections covering root causes, corporate response, fairness of prosecution, legal compliance, and strategic lessons, and closes with a concise three-point summary for executive decision-makers. Each section builds on the previous one, moving from diagnosis to prescription.
Introduction and Background
GlaxoSmithKline (GSK) is the world's fourth-largest pharmaceutical company by sales — after Pfizer, Novartis, and Sanofi — and is a British multinational that operates across biologics, vaccines, and consumer healthcare. The company operates internationally and maintains a very large product mix. China is one of GSK's primary investment focus areas. In July 2013, Chinese police accused GSK of funnelling up to 3 billion yuan (approximately £323 million) through travel agencies to facilitate bribes paid to doctors in order to boost the sale of its medicines. GSK subsequently confirmed that some of its senior Chinese executives appeared to have broken the law ("GSK Under Fire Again For Alleged Corruption in China," 2013). In the preceding three years alone, U.S. authorities had imposed more than £13 billion in fines on pharmaceutical companies, and scrutiny had increasingly shifted toward the activities of "Big Pharma" in emerging markets ("Business Ethics & CSR — GSK Promises to be Good," 2014).
This bribery case has cast a shadow over many companies planning to establish operations in China. From the perspective of the CEO of a U.S.-based company with subsidiaries in the United Kingdom, it is important to understand why GSK became entangled in such activities — and what the business conditions, legal and regulatory framework, and prevailing cultural attitudes in China contributed to that outcome. It is equally important to consider the matter in light of the anti-bribery regulations that apply in the U.S. and the UK, where the company also has operations. This paper examines the ways a U.S.-based company can reduce and minimize the risks of doing business in China (Beijing, 2014).
Create your account
Always verify citation format against your institution’s current style guide requirements.